@article{671a221d598e40cca4cc37dec2d1bf96,
title = "Potential Role of IFNg Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy",
abstract = "Here we review the pathophysiology and management of cytokine release syndrome (CRS) secondary to immunotherapy, and potential options for CRS refractory to IL6 inhibition and glucocorticoids, for which there are no proven treatments. To illustrate, we describe a patient with B-cell acute lymphoblastic leukemia who developed refractory grade 4 CRS following CD19-directed chimeric antigen receptor T-cell therapy, treated with tocilizumab, methylprednisolone, siltuximab, and the IFNγ inhibitor emapalumab, with complete remission from leukemia for 12 months.",
author = "McNerney, {Kevin O.} and DiNofia, {Amanda M.} and Teachey, {David T.} and Grupp, {Stephan A.} and Maude, {Shannon L.}",
note = "Funding Information: D.T. Teachey reports personal fees from Sobi during the conduct of the study; nonfinancial support from Janssen, grants and personal fees from BEAM Therapeutics, and grants from NeoImmune Tech outside the submitted work; and a patent for US2018252727A1 pending. S.A. Grupp reports research and/or clinical trial support from Novartis, Servier, Vertex, and Kite, and has participated in consulting, study steering committees, or scientific/clinical advisory boards for Novartis, Allogene, CBMG, Cellectis, Adaptimmune, Eureka, TCR2, Juno, GlaxoSmithKline, Vertex/CRISPR, and Roche. S.L. Maude reports grants, personal fees, and nonfinancial support from Novartis; personal fees from Wugen; and personal fees and nonfinancial support from Kite outside the submitted work. No disclosures were reported by the other authors. Funding Information: The authors thank Michele Paessler, Hamid Bassiri, and Chakkapong Burudpakdee for development and validation of the serum cytokine panel. D.T. Teachey is supported by grants from the NIH (R01CA263837, R01CA193776, R03CA256550), Leukemia & Lymphoma Society, Alex{\textquoteright}s Lemonade Stand Foundation, and Children{\textquoteright}s Oncology Group. S.L. Maude is supported by grants from the St. Baldrick{\textquoteright}s Foundation–Stand Up To Cancer (SU2CAACR-DT-27-17), V Foundation, and Children{\textquoteright}s Oncology Group. Stand Up To Cancer is a division of the Entertainment Industry Foundation. The indicated SU2C grant is administered by the American Association for Cancer Research, the scientific partner of SU2C. Publisher Copyright: {\textcopyright} 2021 American Association for Cancer Research.",
year = "2022",
month = mar,
day = "1",
doi = "10.1158/2643-3230.BCD-21-0203",
language = "English (US)",
volume = "3",
pages = "90--94",
journal = "Blood cancer discovery",
issn = "2643-3230",
publisher = "NLM (Medline)",
number = "2",
}